FDA
No application listedNo application naming pralmorelin as an active ingredient is listed in Drugs@FDA. Checked 2026-10-05; the control lookup (semaglutide) returned 6 applications.
Drugs@FDA via openFDAGHRP-2: chemistry, literature and regulatory status
Research-use information. This page summarises published literature and regulator records. It is not guidance for use, not medical advice, and not a statement that any material is suitable for use in people or animals.
What is GHRP-2?
GHRP-2, also called pralmorelin, is the synthetic hexapeptide D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2, a growth hormone-releasing peptide that acts at the growth hormone secretagogue receptor. Published work includes a drug profile and diagnostic stimulation-test studies. It is supplied here as a research material for laboratory use only.
What are the chemical facts for GHRP-2?
- Name
- GHRP-2
- Also written
- Pralmorelin; KP-102
- Sequence
- D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2
- Length
- 6 residues
- Molecular formula
C45H55N9O6(matches the formula computed from the sequence)- Average molecular weight
- 818 g/mol
- CAS number
158861-67-7(confirmed in PubChem)- PubChem
- CID 6918245
Chemistry checked against PubChem on 2026-10-05. Where the formula can be computed from the listed sequence, it was, and the two routes agree.
How does the literature describe the mechanism of GHRP-2?
- A drug profile describes pralmorelin as a synthetic growth hormone-releasing peptide from a series developed at Tulane University and Polygen.[3]
- The receptor targeted by growth hormone secretagogues was cloned from pituitary and hypothalamus of swine and humans.[4]
- Two clinical papers describe the GHRP-2 test as a diagnostic stimulation test of pituitary function, and examine its growth hormone and ACTH responses.[1],[2]
Receptor and pathway background: Growth hormone secretagogue receptor.
What has published research on GHRP-2 looked at?
4 studies are cited for GHRP-2. Each is labelled by design below, and each entry says what the paper measured.
- 2 human study
- 1 review
- 1 receptor biology
PubMed returns 237 records for the search terms published on the method page (21 of them with a review publication type, 56 with a clinical-trial publication type), checked 5 October 2026. ClinicalTrials.gov lists 0 registered studies whose intervention matches the name (0 interventional), checked 5 October 2026.
Studies are listed by what they measured. Papers whose titles state an amount or schedule, or describe a clinical outcome of an approved medicine, are not listed. This is a wording rule, not a quality filter; see the method page.
What is the regulatory status of GHRP-2?
EMA
No centrally authorised medicine listedNo centrally authorised procedure in the EMA medicines database (checked 5 October 2026) names pralmorelin as an active substance. National authorisations are not in this dataset.
EMA medicines dataMHRA
No product document foundNo SmPC, PIL or PAR document in MHRA Products matches the exact name "pralmorelin". Checked 2026-10-05; the control lookup (semaglutide) returned 271 documents.
MHRA ProductsWADA
Named, S2.2.4The WADA 2026 Prohibited List, in force 1 January 2026 names GHRP-2 under S2.2.4 (growth hormone releasing factors,). A WADA entry is a sporting rule, not a statement about legality outside sport.
WADA Prohibited List 2026A regulator record is information about a database entry. It is not advice and not a statement that any use is lawful or unlawful in any country. How regulators approach research peptides.
Data dates: regulatory records 2026-10-05; WADA list 2026-10-05.
Which studies are cited for GHRP-2?
[1] Teramoto S, Tahara S, Hattori Y, Kondo A, Morita A. Assessment of anterior pituitary reserve capacity based on growth hormone response to growth hormone-releasing peptide-2 test in the elderly. Growth Horm IGF Res. 2023;71:101545.
Analysed growth hormone response to the GHRP-2 diagnostic test in 65 elderly patients with a non-functioning pituitary tumour.
[2] Suzuki S, Ruike Y, Ishiwata K, Naito K, Igarashi K, Ishida A, et al.. Clinical Usefulness of the Growth Hormone-Releasing Peptide-2 Test for Hypothalamic-Pituitary Disorder. J Endocr Soc. 2022;6:bvac088.
Evaluated the GHRP-2 test as a diagnostic test in patients with hypothalamic-pituitary disorder, including its ACTH response.
[3] Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN. Drugs R D. 2004;5:236-9.
Drug profile of pralmorelin (GHRP-2): its origin, pharmacology and development history.
[4] Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, et al.. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273:974-7.
Cloning of the pituitary and hypothalamic G-protein-coupled receptor targeted by growth hormone secretagogues.
Data dates: citations read from PubMed 2026-10-05.
Where else in the research library is GHRP-2 covered?
Who wrote this page and how is it checked?
Peptency editorial team, last reviewed 5 October 2026. Citations are read back from PubMed, chemistry is checked against PubChem, and regulator records are read from each regulator's own database on the dates shown. The method page lists every source, search term and rule. Corrections are welcome through the contact details on the About page.